Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C48429
http://purl.obolibrary.org/obo/NCIT_C48429
|
|---|---|
| Preferred Name | Yttrium Y-90 Clivatuzumab Tetraxetan |
| Definitions |
A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. |
|---|---|
| prefLabel | Yttrium Y-90 Clivatuzumab Tetraxetan
|
| label | Yttrium Y-90 Clivatuzumab Tetraxetan
|
| PDQ_Closed_Trial_Search_ID | 425350
|
| code | C48429
|
| Has_Target | |
| prefixIRI | NCIT:C48429
|
| in_subset |
See more
See less
|
| Display_Name | Yttrium Y-90 Clivatuzumab Tetraxetan
|
| Preferred_Name | Yttrium Y-90 Clivatuzumab Tetraxetan
|
| FDA_UNII_Code | 2L271110ED
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C16H25N5O7.Y
|
| Maps_To | Yttrium Y-90 Clivatuzumab Tetraxetan
|
| CAS_Registry | 943976-23-6
|
| NCI_Drug_Dictionary_ID | 425350
|
| Legacy Concept Name | Yttrium_Y_90_DOTA_Monoclonal_Antibody_HuPAM4
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of advanced pancreatic cancer. HuPAM4 is a monoclonal antibody that can locate and bind to pancreatic cancer cells. It is linked to a radioactive substance called yttrium Y90, which may help kill cancer cells. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 is a type of radioimmunoconjugate.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 425350
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1541526
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |